
    
      The objective of this study was to compare the bioavailability and characterise the
      pharmacokinetics profile of the sponsor formulation Quetiapine fumarate tablets 300 mg of Dr.
      Reddy's Laboratories Limited, India with respect to reference formulation Seroquel tablets
      300 mg of Astrazeneca Pharmaceuticals, USA in adults schizophrenia patients under fasting
      condition.

      54 subjects were dosed and were enrolled in the study.
    
  